Clinical Trial Update: A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of Temferon in multiple myeloma with early relapse after frontline therapy; trial terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Temferon (temferon)

Snippet

Sponsor: Genenta Science | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-01-28